pulmonary arterial hypertension
Conditions
Interventions
Control group:Traditional diuretic
Experimental group:Tolvaputan
Sponsors
Center for Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing(100037), China
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >=18 years; 2. The patient was confirmed by the right heart catheter of the first class of pulmonary hypertension (PAH), hemodynamic compliance: pulmonary artery average pressure (MPAP) >=25mmHg, pulmonary small artery ?pression (PAWP) 15mmHg, PVR3wood units. And there are clinical symptoms and signs of right heart failure: difficulty breathing after activity, lower limb edema, neck vein anger, ascertic water, etc. 3. New York Heart Association (NYHA) heart function rating are III IV; 4. The targeted drugs used to treat PAH are relatively stable; 5. Not combined with serious cerebrovascular, liver, kidney, lung and other organ tissue diseases; 6. No glucosticoids and immunosuppressants were used in the first 3 months of the study; 7. Volunteer to participate and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) Installation of cycle aids; (2) Diagnosed as active myocarditis or amyloid cardiomyopathy; (3) Suspected obstruction hypertrophomyopathy, severe aortic stenosis; (4) Poorly controlled diabetes, an empty stomach blood sugar of more than 12.21mmol/L; (5) No urine, urethra stenosis, stones, tumors, etc. caused by urination disorders; (6) Acute myocardial infarction, persistent roomary titration or atrial fibrillation, cerebrovascular accident within 30d before screening; (7) Patients with a history of allergies or specific reactions to benzodiazepines (Mozavaptan hydrochloride, benapri hydrochloric acid); (8) Any of the following laboratories examined abnormalities: serum creatinine> normal limit of 2.5 times, serum sodium >145mmol/L, serum potassium >5.5mmol/L. (9) Pregnant women, lactating women, patients who may be pregnant or have a pregnancy plan; (10) Other taboos associated with the use of Tovaputan; (11) Tovaputan was used in the first 3 months of the study, including listed Tovaputan or in clinical studies. (12) In addition to the above, the researchers determined that patients who participated in this trial were not suitable.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| weight;The amount of urine; | — |
Secondary
| Measure | Time frame |
|---|---|
| NT-proBNP;the fuction of right heart; | — |
Countries
China
Contacts
Public ContactZhihui Zhao
Center for Pulmonary Vascular Diseases, National Center for Cardiovascular Diseases and Fuwai Hospital, CAMS and PUMC, Beijing(100037), China
Outcome results
None listed